Showing results (11-20 of 46) with videos related to
Sort By:
Pageof 5
American Journal of Alzheimer'S Disease and Other Dementias|March 9, 2023
Burden of Illness Among Patients with Psychosis due to Dementia with Lewy Bodies and Other DementiasMonica Frazer, Nazia Rashid, Scott Bunner, et al.Therapeutic Advances in Neurological Disorders|March 13, 2024
The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson's disease psychosis: a 16-week, single-arm, open-label studyVirgilio G H Evidente, Daryl DeKarske, Bruce Coate, et al.International Clinical Psychopharmacology|March 31, 2022
Medicare claims analysis of agents used to manage dementia-related psychosis: a treatment pattern studyNazia Rashid, James B Wetmore, Muna Irfan, et al.International Journal of Geriatric Psychiatry|July 31, 2020
Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysisClive G Ballard, Bruce Coate, Victor Abler, et al.Clinical Parkinsonism & Related Disorders|May 21, 2024
Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosisStuart H Isaacson, Rajesh Pahwa, Fernando Pagan, et al.Neuropsychological Rehabilitation|March 9, 2019
Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and cliniciansCarey Wexler Sherman, Ravi Iyer, Victor Abler, et al.Movement Disorders : Official Journal of the Movement Disorder Society|July 31, 2016
Minimally clinically important decline in the parkinsonian variant of multiple system atrophyFlorian Krismer, Klaus Seppi, Gregor K Wenning, et al.BMC Psychiatry|July 13, 2020
Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesiaStanley N Caroff, Fan Mu, Rajeev Ayyagari, et al.Journal of Alzheimer'S Disease : JAD|March 1, 2024
Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B StudyGus Alva, Wiesław J Cubała, Ana Berrio, et al.Frontiers in Neurology|October 24, 2022
Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosisVictor Abler, Cecilia Brain, Clive Ballard, et al.Pageof 5